News | February 04, 2015

JHS joins growing network for brain imaging agent

Lantheus, Jubilant HollisterStier, Neurolite, manufacturing, radiopharmaceutical

Image courtesy of Lantheus Medical Imaging Inc.


February 4, 2015 — Lantheus Medical Imaging Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) allowing Jubilant HollisterStier (JHS) to be a new manufacturer for its proprietary brain perfusion imaging agent Neurolite. Neurolite is a technetium-based single-photon emission computed tomography (SPECT) radiopharmaceutical agent used to identify the area within the brain where blood flow has been blocked or reduced due to stroke.

The radiotracer is indicated as an adjunct to conventional computed tomography (CT) or magnetic resonance imaging (MRI) in the localization of stroke in patients in whom stroke has already been diagnosed. Neurolite is not indicated for assessment of functional viability of brain tissue or for distinguishing between stroke and other brain lesions.

Recently, Lantheus received approval from the Therapeutic Goods Administration (TGA) of Australia and the Pharmaceutical and Medical Devices Agency of Japan for JHS-manufactured Neurolite.

For more information: www.lantheus.com


Related Content

News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Radiology Business

January 23, 2024 — Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals ...

Time January 23, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

January 18, 2024 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labeling ...

Time January 18, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Over the past several years, technological advancements have driven the development of more precise and targeted ...

Time January 16, 2024
arrow
Subscribe Now